Neurocrine Biosciences, Inc. (NBIX)
NASDAQ: NBIX · Real-Time Price · USD
164.45
+1.04 (0.64%)
Aug 10, 2026, 3:12 PM EDT - Market open
Neurocrine Biosciences Ratios and Metrics
Market cap in millions USD. Fiscal year is January - December.
Millions USD. Fiscal year is Jan - Dec.
Total Valuation
Fiscal Year | Current | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Aug '26 Aug 10, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
| 16,716 | 14,197 | 13,568 | 13,005 | 11,526 | 8,083 | |
Market Cap Growth | 31.23% | 4.64% | 4.33% | 12.83% | 42.60% | -9.81% |
Enterprise Value | 16,788 | 13,132 | 12,947 | 12,402 | 10,800 | 7,812 |
Last Close Price | 164.45 | 141.83 | 136.50 | 131.76 | 119.44 | 85.17 |
Price Ratios
Fiscal Year | Current | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Aug '26 Aug 10, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
PE Ratio | 23.95 | 30.37 | 41.49 | 53.34 | 76.56 | 92.58 |
Forward PE | 14.62 | 15.87 | 18.15 | 21.34 | 22.53 | 24.55 |
PEG Ratio | 0.35 | 0.75 | 0.31 | 0.65 | 0.66 | 1.12 |
PS Ratio | 4.88 | 4.96 | 5.76 | 6.89 | 7.74 | 7.13 |
PB Ratio | 4.49 | 4.36 | 5.24 | 5.83 | 6.75 | 5.88 |
P/TBV Ratio | 17.59 | 4.47 | 5.47 | 6.06 | 7.07 | 6.07 |
P/FCF Ratio | 18.93 | 18.96 | 24.35 | 35.96 | 35.70 | 34.67 |
P/OCF Ratio | 18.34 | 18.14 | 22.79 | 33.35 | 33.96 | 31.51 |
EV Ratios
Fiscal Year | Current | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Aug '26 Aug 10, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
EV/Sales Ratio | 4.90 | 4.59 | 5.50 | 6.57 | 7.25 | 6.89 |
EV/EBITDA Ratio | 19.65 | 20.23 | 21.67 | 45.56 | 40.81 | 68.89 |
EV/EBIT Ratio | 20.82 | 21.21 | 22.69 | 49.43 | 43.37 | 76.21 |
EV/FCF Ratio | 19.01 | 17.54 | 23.24 | 34.30 | 33.45 | 33.51 |
Financial Efficiency
Fiscal Year | Current | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Aug '26 Aug 10, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
Debt / Equity Ratio | 0.11 | 0.13 | 0.18 | 0.12 | 0.05 | 0.32 |
Debt / EBITDA Ratio | 0.48 | 0.64 | 0.76 | 1.57 | 0.99 | 3.88 |
Debt / FCF Ratio | 0.46 | 0.56 | 0.82 | 1.19 | 0.81 | 1.89 |
Net Debt / Equity Ratio | 0.00 | -0.33 | -0.24 | -0.27 | -0.42 | -0.20 |
Net Debt / EBITDA Ratio | 0.01 | -1.64 | -1.04 | -2.22 | -2.74 | -2.39 |
Net Debt / FCF Ratio | 0.01 | -1.42 | -1.11 | -1.67 | -2.25 | -1.16 |
Asset Turnover | 0.68 | 0.69 | 0.68 | 0.67 | 0.67 | 0.60 |
Inventory Turnover | 0.27 | 0.82 | 0.71 | 1.08 | 0.71 | 0.49 |
Quick Ratio | 1.46 | 2.92 | 3.06 | 2.25 | 2.49 | 3.65 |
Current Ratio | 1.87 | 3.39 | 3.40 | 2.45 | 2.70 | 3.96 |
Return on Equity (ROE) | 20.31% | 16.38% | 14.16% | 12.68% | 10.03% | 7.17% |
Return on Assets (ROA) | 11.94% | 10.06% | 11.50% | 6.71% | 8.10% | 4.76% |
Return on Invested Capital (ROIC) | 19.23% | 20.21% | 22.27% | 14.46% | 17.26% | 9.84% |
Return on Capital Employed (ROCE) | 18.99% | 17.44% | 19.65% | 11.33% | 13.62% | 6.07% |
Yields
Fiscal Year | Current | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Aug '26 Aug 10, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
Earnings Yield | 4.28% | 3.29% | 2.41% | 1.87% | 1.31% | 1.08% |
FCF Yield | 5.28% | 5.27% | 4.11% | 2.78% | 2.80% | 2.88% |
Buyback Yield / Dilution | -0.78% | 1.16% | -2.67% | -2.12% | -1.02% | -0.10% |
Total Shareholder Return | -0.78% | 1.16% | -2.67% | -2.12% | -1.02% | -0.10% |